Blog
RSS FeedPosted by Michael Wonder on 07 May 2020
How are incremental cost effectiveness, contextual considerations, and other benefits viewed in health technology assessment recommendations in the United States?
7 May 2020 - This study reviews ICER assessments to explore the relationship between incremental cost-effectiveness, other benefits, and contextual factors ...
Posted by Michael Wonder on 01 May 2020
ICER presents alternative pricing models for remdesivir as a treatment for COVID-19
1 May 2020 - Models present prices according to two different paradigms: “cost recovery” approach and traditional cost-effectiveness analysis. ...
Posted by Michael Wonder on 01 May 2020
The global imperative to make cancer medications affordable
1 May 2020 - The value of any medication is determined by the magnitude of the clinical benefit (improved survival and ...
Posted by Michael Wonder on 30 Apr 2020
Using QALYs versus DALYs to measure cost effectiveness: how much does it matter?
30 April 2020 - Quality-adjusted life-years and disability-adjusted life-years are commonly used in cost effectiveness analysis to measure health benefits. Gent ...
Posted by Michael Wonder on 27 Apr 2020
ICER releases evidence report on treatments for cystic fibrosis
27 April 2020 - Evidence on Trikafta provides high confidence of a substantial net health benefit for patients; additional benefits accrue ...
Posted by Michael Wonder on 23 Apr 2020
ICER Appoints Jon Campbell as Senior Vice President for Health Economics
23 April 2020 - In September, Jonathan D. Campbell, PhD, will become Senior Vice President for Health Economics at the Institute ...
Posted by Michael Wonder on 17 Apr 2020
America can afford a world class health care system. Why don’t we have one?
14 April 2020 - In March, Congress passed a coronavirus bill including $3.1 billion to develop and produce drugs and ...
Posted by Michael Wonder on 16 Apr 2020
ICER Appoints Yvette Venable as Vice President of Patient Engagement
16 April 2020 - The Institute for Clinical and Economic Review has announced the appointment of Yvette Venable as the organisation’s ...
Posted by Michael Wonder on 19 Mar 2020
Getting value right: the case for indirect benefits
19 March 2020 - According to the most recent estimates from the Centers for Medicare and Medicaid Services Office of the ...
Posted by Michael Wonder on 19 Mar 2020
ICER releases draft evidence report on obeticholic acid for non-alcoholic steatohepatitis
19 March 2020 - Public comment period on preliminary draft now open until 24 June 2020; requests to make oral comment ...
Posted by Michael Wonder on 18 Mar 2020
ICER indefinitely postpones public meetings for sickle cell disease and cystic fibrosis; expands other assessment timelines up to three months
18 March 2020 - Updated schedules are intended to enable participating clinical experts and patient advocates to focus on caring for ...
Posted by Michael Wonder on 15 Mar 2020
ICER posts draft scoping documents on bladder cancer and digital apps for opioid use disorder
13 March 2020 - Documents open to public comment until 2 April 2020. ...
Posted by Michael Wonder on 13 Mar 2020
ICER releases evidence report on treatments for sickle cell disease
12 March 2020 - Three new treatments use different mechanisms to improve patient outcomes, offering important options for patients. ...
Posted by Michael Wonder on 03 Mar 2020
ICER to postpone assessment of gene therapy for beta thalassemia
3 March 2020 - Due to delay in regulatory submission, ICER will reinitiate assessment at a future date — ...
Posted by Michael Wonder on 25 Feb 2020
ICER issues final report and policy recommendations on acute treatments for migraine
25 February 2020 - Evidence on new agents lasmiditan, ubrogepant, and rimegepant judged inadequate to demonstrate superiority over more affordable triptans. ...